Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy
Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...
Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500...
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...
Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of...
Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...
Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an...
Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...
Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...
Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1...
Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...
Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...
BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...